Segment reporting (Tables)

6 Months Ended

Jan. 31, 2021

Segment Reporting [Abstract]

Schedule of financial information represents the operating results of the reportable segments

Three months ended January 31, 2021	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues – Services and Products	$	23,988		$	7,478		-			-		$	31,466
Operating costs and expenses:
Cost of revenues		11,708			3,937		-			-			15,645
Research and development		160			633	$	13			-			806
Selling, general and administrative		6,425			2,593		16		$	1,979			11,013
Legal and related expenses		71			1		-			2,220			2,292
Total operating costs and expenses		18,364			7,164		29			4,199			29,756
Operating income (loss)		5,624			314		(29	)		(4,199	)		1,710
Other income (expense):
Interest		(4	)		8		-			(53	)		(49	)
Other		14			2		-			-			16
Foreign exchange gain		-			625		-			-			625
Net income (loss)	$	5,634		$	949	$	(29	)	$	(4,252	)	$	2,302
Depreciation and amortization included above	$	381		$	188	$	-		$	66		$	635
Share-based compensation included in above:
Selling, general and administrative		10			16		-			136			162
Cost of revenues		14			-		-			-			14
Total	$	24		$	16	$	-		$	136		$	176
Capital expenditures	$	341		$	154	$	-		$	11		$	506

Three months ended January 31, 2020	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues	$	12,513		$	6,871		-			-		$	19,384
Operating costs and expenses:
Cost of revenues		10,243			3,332		-			-			13,575
Research and development		373			503		189			-			1,065
Selling, general and administrative		5,895			2,530		-			2,268			10,693
Legal fee expense		38			1		-			2,021			2,060
Total operating costs and expenses		16,549			6,366		189			4,289			27,393
Operating income (loss)		(4,036	)		505		(189	)		(4,289	)		(8,009	)
Other income (expense):
Interest		(10	)		16		-			165			171
Other		16			7		-			49			72
Foreign exchange gain		-			79		-			-			79
Net (loss) income	$	(4,030	)		607		(189	)		(4,075	)		(7,687	)
Depreciation and amortization included above	$	392			253		-			65			710
Share-based compensation included in above:
Selling, general and administrative		33			22		-			247			302
Total	$	33			22		-			247			302
Capital expenditures	$	142			18		-			-			160

Six months ended January 31, 2021	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues – Services and Products	$	45,211		$	14,910		-			-		$	60,121
Operating costs and expenses:
Cost of revenues		24,703			7,700		-			-			32,403
Research and development		281			1,225	$	46			-			1,552
Selling, general and administrative		12,523			5,038		33		$	3,433			21,027
Legal and related expenses		96			6		-			2,830			2,932
Total operating costs and expenses		37,603			13,969		79			6,263			57,914
Operating income (loss)		7,608			941		(79	)		(6,263	)		2,207
Other income (expense):
Interest		(10	)		18		-			(108	)		(100	)
Other		29			4		-			-			33
Foreign exchange gain					461		-			-			461
Net income (loss)	$	7,627		$	1,424	$	(79	)	$	(6,371	)	$	2,601
Depreciation and amortization included above	$	790		$	373	$	-		$	132		$	1,295
Share-based compensation included in above:
Selling, general and administrative		19			32		-			265			316
Cost of revenues		27			-		-			-			27
Total	$	46		$	32	$	-		$	265		$	343
Capital expenditures	$	881		$	198	$	-		$	44		$	1,123

Six months ended January 31, 2020	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues – Services and Products	$	25,293		$	14,298			-			-		$	39,591
Operating costs and expenses:
Cost of revenues		21,218			6,878			-			-			28,096
Research and development		723			1,019		$	377			-			2,119
Selling, general and administrative		12,110			5,287			-		$	4,435			21,832
Legal and related expenses		88			1			-			3,667			3,756
Total operating costs and expenses		34,139			13,185			377			8,102			55,803
Operating income (loss)		(8,846	)		1,113			(377	)		(8,102	)		(16,212	)
Other income (expense):
Interest		(22	)		34			-			396			408
Other		19			(5	)		-			185			199
Foreign exchange gain		-			270			-			-			270
Net income (loss)	$	(8,849	)	$	1,412		$	(377	)	$	(7,521	)	$	(15,335	)
Depreciation and amortization included above	$	801		$	503		$	-		$	130		$	1,434
Share-based compensation  included in above:
Selling, general and administrative.		67			44			-			410			521
Total	$	67		$	44		$	-		$	410		$	521
Capital expenditures	$	289		$	145		$	-		$	-		$	434